Journal of Clinical & Experimental Oncology · 2013 · 19 citations · 89 references
MedicineOncologyPharmacologyChemotherapyDrug DeliveryMolecular OncologyCancer Drug DeliveryChemotherapy ResistanceCytotoxic ChemotherapyOncology PharmacologyTargeted Cancer TherapyTargeted TherapyChemotherapy DeliveryGemcitabine-based TherapyPlasma Half-life ExtensionPyrimidine AnalogsRibonucleotide IncorporationTargeted Combination ChemotherapyTargeted Therapy-induced ApoptosisTumor-targeted Drug Delivery
INTRODUCTION: Gemcitabine is a pyrimidine nucleoside analog that becomes triphosphorylated and competitively inhibits cytidine incorporation into DNA strands. Diphosphorylated gemcitabine irreversibly inhibits ribonucleotide reductase thereby preventing deoxyribonucleotide synthesis. Functioning as a potent chemotherapeutic, gemcitabine decreases neoplastic cell proliferation and induces apoptosis which accounts for its effectiveness in the clinical treatment of several leukemia and carcinoma cell types. A brief plasma half-life due to rapid deamination, chemotherapeutic-resistance and sequelae restrict gemcitabine utility in clinical oncology. Selective "targeted" gemcitabine delivery represents a molecular strategy for prolonging its plasma half-life and minimizing innocent tissue/organ exposure. METHODS: ]. RESULTS: ] or gemcitabine alone. CONCLUSION: ] compared to benzimidazole tubulin/microtubule inhibitors.
89
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski Mx, Lofgren Ja, Lewis Gd et al. · PubMed · 1999 · 654 citations
Active Nanodiamond Hydrogels for Chemotherapeutic Delivery
Houjin Huang, Erik Pierstorff, Eiji O̅sawa et al. · Nano Letters · 2007 · 552 citations
Pharmacy, Oncology, Pharmacology +17
Christoph A. Ritter, Marianela Pérez-Torres, Cammie Rinehart et al. · Clinical Cancer Research · 2007 · 506 citations · Full text
Medicine, Oncology, Pharmacology +13